tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Catalent (CTLT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRNResearch Report), Illumina (ILMNResearch Report) and Catalent (CTLTResearch Report).

BioMarin Pharmaceutical (BMRN)

In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $115.00. The company’s shares closed last Wednesday at $84.33.

According to TipRanks.com, Schwartz is a 4-star analyst with an average return of 4.5% and a 44.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $112.36, representing a 33.2% upside. In a report issued on January 4, Piper Sandler also maintained a Buy rating on the stock with a $121.00 price target.

See today’s best-performing stocks on TipRanks >>

Illumina (ILMN)

Leerink Partners analyst Puneet Souda maintained a Hold rating on Illumina yesterday. The company’s shares closed last Wednesday at $367.88, close to its 52-week low of $341.03.

According to TipRanks.com, Souda is a 3-star analyst with an average return of 3.0% and a 43.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Illumina has an analyst consensus of Hold, with a price target consensus of $432.00, representing a 17.4% upside. In a report released today, Morgan Stanley also initiated coverage with a Hold rating on the stock with a $425.00 price target.

Catalent (CTLT)

In a report released yesterday, David Windley from Jefferies maintained a Buy rating on Catalent, with a price target of $165.00. The company’s shares closed last Wednesday at $116.06.

According to TipRanks.com, Windley is a top 100 analyst with an average return of 19.3% and a 75.9% success rate. Windley covers the Healthcare sector, focusing on stocks such as Stevanato Group, IQVIA Holdings, and UnitedHealth.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Catalent with a $159.14 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed